Editorial Board
Kun Meng
Beijing Shenogen Pharma Group
Editorial leadership for International Journal of Translational Research
Research interests
- Translation Research Of Anti-Cancer Drugs
Biography
- Dr. Kun Meng is a co-founder, Chairman & CEO of Beijing Shenogen Pharma Group.
- He has more than 15-year research experience in molecular biology, small molecule drug and pharmacology, as well as over 10-year experience of drug development and management in pharma industry.
- Dr. Meng was CEO of a traditional Chinese medicine technology company and Chief Technical Officer of Jianxin Pharmaceuticals Co., Ltd.
- Dr. Meng received Ph.D. degree of Biochemistry from Chinese Academy of Sciences. He completed postdoctoral training in Harvard and Washington University School of Medicine, and he also received MPA degree from Kennedy School at Harvard.
- Dr. Meng was elected to the National Thousand Talents, Beijing High-level Talents Organization and Beijing Scientific Leader Program.
Considering IJTR for your work?
This journal is guided by Kun Meng (Beijing Shenogen Pharma Group) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.